Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, has announced that it has entered into definitive securities purchase agreements for a private placement expected to result in gross proceeds of approximately US$50 million, before deducting placement agent fees and offering expenses, and an additional approximately US$64 million of gross proceeds if the accompanying warrants are exercised in full for cash.
Latham & Watkins LLP represented the placement agent in the transaction with a Capital Markets team led by New York partner Nathan Ajiashvili, with associates Katie Mehary and Jenny Li.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.
